abdalla abotaleb | World Health Organization (original) (raw)

Papers by abdalla abotaleb

Annals of Oncology, Jul 1, 2019

Annals of Oncology, Jun 1, 2018

observed. MMR by IHC revealed deficiency in 12 (17.1%) out of 70 patients evaluated, of which 21.... more observed. MMR by IHC revealed deficiency in 12 (17.1%) out of 70 patients evaluated, of which 21.4% were right sided and 14.2% were left sided. All of these had BRAF wild type suggestive of Lynch syndrome. Conclusion: To our knowledge this is the first study to evaluate MMR deficiency by IHC in Indian patients with tumour localisation. 12 (17.1%) patients with MMR deficiency qualified as likely candidates for immunotherapy and these families would benefit from cancer screening for Lynch syndrome and genetic counselling. The frequency of KRAS mutation was 39% which is similar to worldwide reports and in our study, by evaluating NRAS and BRAF mutants, we were able to classify an additional 10.2% patients as likely non-responders to anti-EGFR therapy. In present therapeutic landscape, it is imperative to test genetic biomarkers for colorectal cancer patients.

Value in Health, Oct 1, 2017

to home services fees. 41% of respondents bought a walking-aid device and 23% a manual wheelchair... more to home services fees. 41% of respondents bought a walking-aid device and 23% a manual wheelchair. ConClusions: These results indicate that, depending upon services, about 60% of patients and 40% of caregivers dedicate part of their financial resources to cover non-medical costs directly linked to MS.

Value in Health, Oct 1, 2017

1768 CABG patients had purchased lipid-modifying agents during the three years before, and 94.9% ... more 1768 CABG patients had purchased lipid-modifying agents during the three years before, and 94.9% and 96.8% during the year after the procedure, respectively. Beta blocking agents were purchased by 84.9% of PCI patients before and by 87.9% after the procedure, and by 86.3% of CABG patients before and 97.1% after the operation. In CABG patients the purchase of organic long acting nitrates fell from 59.7% before to 10.1% after the operation but remained almost constant in PCI patients (64.3% vs. 54.4%). Use of ADP receptor blocking agents increased in PCI patients from the preintervention 26.3% to the post-intervention 83.9%. Greater use of hospital services before and after the interventions had an incremental effect on medication purchases. ConClusions: Based on information on drug purchases, real-world use of recommended pharmacological therapy before and after revascularization complied both in PCI and CABG patients surprisingly well with current guidelines.

Journals of Clinical Cases & Reports, Jun 30, 2021

Value in Health, Oct 1, 2018

50mg (from sitagliptin 100mg). CONCLUSIONS: Despite four years' treatment less than one third of ... more 50mg (from sitagliptin 100mg). CONCLUSIONS: Despite four years' treatment less than one third of patients with T2DM and RI had their DPP-4i therapy adjusted. Presentation of RI during DPP-4i treatment is rarely associated with a prompt therapy adjustment. There appears to be significant clinical inertia between initiation of DPP-4is and therapy adjustment in T2DM patients with either prevalent or incident RI.

Value in Health, Oct 1, 2017

of prostate cancer patients with bone metastases (patients who were specifically coded as "Castra... more of prostate cancer patients with bone metastases (patients who were specifically coded as "Castration-resistant prostate cancer" (ICD-10, C61) and "8848040" (Japan MEDIS-DC)), who had been treated with ADT and a CRPC-targeted treatment (according to approved indication). Results: 276 patients were identified, with a mean age of 71.0 y.o (S.D. 8.7). Visceral metastasis was present in 43.8% of the patients, with the most common site being the lungs (34.4%). The mean treatment period for mCRPC was 34 months. 87.4% had undergone medical Androgen Deprivation Therapy (ADT), with 5.8% undergoing surgical ADT. Radiation therapy was given to 29.3% of patients, and 40% had been treated with opioids. 89.5% of the patients had undergone bone scanning. There were an average number of 67 outpatient visits and 2.8 inpatient admissions per patient during the treatment period. A mean of 9.9 laboratory and imaging examinations in the year prior to CRPC diagnosis was observed, increasing to a mean 28.6 one year post-diagnosis. The most common diagnostic and imaging combination done prior to mCRPC diagnosis was bone scintigraphy, CT, PSA, and blood biochemistry test. Mean per patient monthly costs increased 6-fold from prior to CRPC to post-CRPC diagnosis. ConClusions: Metastatic castration-resistant prostate cancer brings about increased resource use for patients in Japan, with a threefold increase in diagnostic and monitoring tests, increased hospital visits, and increased monthly per patient costs as a result of diagnosis.

Annals of Oncology, 2020

p< 0.01), n-6/n-3 (p¼0.042) as compared with locoregional CRC, was noted for patients with liver ... more p< 0.01), n-6/n-3 (p¼0.042) as compared with locoregional CRC, was noted for patients with liver metastases. ROC curve was plotted for the panel of metabolites to demonstrate the ability to predict the presence of liver metastases or locoregional CRC. The area under the ROC curve was 0.90 with a sensitivity of 0.79 and a specificity of 0.89. We found the list of metabolites capable of identifying differences between patients with liver metastases and extrahepatic metastases: serum levels of myristic acid (C14:0), linoleic acid (C18:2;n-6), phenylalanine, threonine were lower and glutamine, glucose, butanoic acid, histidine, and mannose were more abundant in extrahepatic metastases in comparison with patients with liver metastases (p< 0,01-0,05). In erythrocyte membranes the decreased content of C12:

Value in Health, 2018

recommendations were assigned to the LHUs, in the under-use areas, where there is indication but ... more recommendations were assigned to the LHUs, in the under-use areas, where there is indication but there's no prescription, and areas of over-use, where there's a prescription but there is no indication. With respect to LMWH, an indicator has been assigned that measures the percentage of patients treated with LMWH with a duration of therapy greater than the maximum duration reported in the SPC. The choice of indicators was shared with the clinicians. To LHUs has been assigned the mission of disseminating the indicators through audit initiatives with the prescribers. RESULTS: In the two-year period 2016-2017, regional expenditure by LMWH decreased by over V 4 million, compared to an almost stable trend in the years preceding the introduction of the indicators. The overall performance of the indicator improved by 2%, with peaks of over 4% in some LHUs. The LHUs that have improved the performance have reduced the cost for patient treated with LMWH. CONCLUSIONS: Through the application of appropriateness indicator, leading to an improvement in the health outcomes, a financial objective has been achieved, contributing to the sustainability of the RHS.

European Journal of Cancer, 2017

disease, significant benefit consideration and applicant categorization (Table 1). At the time of... more disease, significant benefit consideration and applicant categorization (Table 1). At the time of OD application, 41.6% of products with OD for rare neoplastic disorders was in preclinical phase, while this was 65.1% of OD for other rare indications (p < 005). Thirty percent of agents for rare neoplastic disorders reached phase 1 clinical trials, whilst this was only 19.3% of agents for other rare indications (p < 005). The same trend was observed for the stage of development at the time of the latest annual report. Conclusion: The products that have been granted OD for rare neoplastic disorders are at a later stage of development compared to OD products for other rare indications. Conflict of interest: Advisory Board: MC is a member of the Scientific Advice Working Party (SAWP) at European Medicines Agency (EMA); KL is head of Orphan Medicines at European Medicines Agency (EMA). Other Substantive Relationships: A donation from Sanofi-Genzyme to KU Leuven covered some research costs; KP is funded by Flanders Innovation & Entrepreneurship.

EC Clinical and Medical Case Reports, Apr 28, 2021

Patients suffering from chronic inflammatory rheumatism are vulnerable; they have an increased ri... more Patients suffering from chronic inflammatory rheumatism are vulnerable; they have an increased risk of bacterial and viral infections, related to the systemic and dysimmune inflammation of the chronic disease and the use of various immunosuppressive therapies. This risk explains the practice of periodic preventive vaccination adopted by all. As a result, patients with chronic inflammatory rheumatism (RIC) are more likely to contract COVID-19 and present severe forms. As with various international societies, the members of the two Algerian rheumatology societies (SAR "Algerian Society for Rheumatology" and LAAR "The Algerian League Against Rheumatism") propose these recommendations. They include general and preventive measures relating to the different situations encountered; management of patients without signs of Covid-19 (SCov-), management of suspected cases (SCov+), management of confirmed cases (SCov+) and management of newly diagnosed cases, recommendations for specific situations, those relating to pregnant women and vaccinations.

EC Clinical and Medical Case Reports, Apr 28, 2021

Journal of Clinical Oncology and Cancer Research, 2021

Journal of Clinical Oncology and Cancer Research, 2021

Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is ... more Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient’s outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols should be implemented during COVID -19. Pandemic and how innovative medicines can achieve the previous objectives.

Research Journal of Oncology, 2019

Background: Head and neck cancer accounts for a range of 4-14% of all cancer cases seen. It is es... more Background: Head and neck cancer accounts for a range of 4-14% of all cancer cases seen. It is estimated to be 3700 new cases/year. Locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) accounts for 47.5-75% of all head and neck cancer. With the development of innovative and targeted therapy for treatment of some questions was raised from payer side need an answer such as: are these innovative products worthy for reimbursement? What is the impact on budget? What is the appropriate use and indication for these products to enhance outcomes and utilize resources?

EC Clinical and Medical Case Reports, Sep 30, 2021

Annals of Oncology, Jul 1, 2019

Annals of Oncology, Jun 1, 2018

observed. MMR by IHC revealed deficiency in 12 (17.1%) out of 70 patients evaluated, of which 21.... more observed. MMR by IHC revealed deficiency in 12 (17.1%) out of 70 patients evaluated, of which 21.4% were right sided and 14.2% were left sided. All of these had BRAF wild type suggestive of Lynch syndrome. Conclusion: To our knowledge this is the first study to evaluate MMR deficiency by IHC in Indian patients with tumour localisation. 12 (17.1%) patients with MMR deficiency qualified as likely candidates for immunotherapy and these families would benefit from cancer screening for Lynch syndrome and genetic counselling. The frequency of KRAS mutation was 39% which is similar to worldwide reports and in our study, by evaluating NRAS and BRAF mutants, we were able to classify an additional 10.2% patients as likely non-responders to anti-EGFR therapy. In present therapeutic landscape, it is imperative to test genetic biomarkers for colorectal cancer patients.

Value in Health, Oct 1, 2017

to home services fees. 41% of respondents bought a walking-aid device and 23% a manual wheelchair... more to home services fees. 41% of respondents bought a walking-aid device and 23% a manual wheelchair. ConClusions: These results indicate that, depending upon services, about 60% of patients and 40% of caregivers dedicate part of their financial resources to cover non-medical costs directly linked to MS.

Value in Health, Oct 1, 2017

1768 CABG patients had purchased lipid-modifying agents during the three years before, and 94.9% ... more 1768 CABG patients had purchased lipid-modifying agents during the three years before, and 94.9% and 96.8% during the year after the procedure, respectively. Beta blocking agents were purchased by 84.9% of PCI patients before and by 87.9% after the procedure, and by 86.3% of CABG patients before and 97.1% after the operation. In CABG patients the purchase of organic long acting nitrates fell from 59.7% before to 10.1% after the operation but remained almost constant in PCI patients (64.3% vs. 54.4%). Use of ADP receptor blocking agents increased in PCI patients from the preintervention 26.3% to the post-intervention 83.9%. Greater use of hospital services before and after the interventions had an incremental effect on medication purchases. ConClusions: Based on information on drug purchases, real-world use of recommended pharmacological therapy before and after revascularization complied both in PCI and CABG patients surprisingly well with current guidelines.

Journals of Clinical Cases & Reports, Jun 30, 2021

Value in Health, Oct 1, 2018

50mg (from sitagliptin 100mg). CONCLUSIONS: Despite four years' treatment less than one third of ... more 50mg (from sitagliptin 100mg). CONCLUSIONS: Despite four years' treatment less than one third of patients with T2DM and RI had their DPP-4i therapy adjusted. Presentation of RI during DPP-4i treatment is rarely associated with a prompt therapy adjustment. There appears to be significant clinical inertia between initiation of DPP-4is and therapy adjustment in T2DM patients with either prevalent or incident RI.

Value in Health, Oct 1, 2017

of prostate cancer patients with bone metastases (patients who were specifically coded as "Castra... more of prostate cancer patients with bone metastases (patients who were specifically coded as "Castration-resistant prostate cancer" (ICD-10, C61) and "8848040" (Japan MEDIS-DC)), who had been treated with ADT and a CRPC-targeted treatment (according to approved indication). Results: 276 patients were identified, with a mean age of 71.0 y.o (S.D. 8.7). Visceral metastasis was present in 43.8% of the patients, with the most common site being the lungs (34.4%). The mean treatment period for mCRPC was 34 months. 87.4% had undergone medical Androgen Deprivation Therapy (ADT), with 5.8% undergoing surgical ADT. Radiation therapy was given to 29.3% of patients, and 40% had been treated with opioids. 89.5% of the patients had undergone bone scanning. There were an average number of 67 outpatient visits and 2.8 inpatient admissions per patient during the treatment period. A mean of 9.9 laboratory and imaging examinations in the year prior to CRPC diagnosis was observed, increasing to a mean 28.6 one year post-diagnosis. The most common diagnostic and imaging combination done prior to mCRPC diagnosis was bone scintigraphy, CT, PSA, and blood biochemistry test. Mean per patient monthly costs increased 6-fold from prior to CRPC to post-CRPC diagnosis. ConClusions: Metastatic castration-resistant prostate cancer brings about increased resource use for patients in Japan, with a threefold increase in diagnostic and monitoring tests, increased hospital visits, and increased monthly per patient costs as a result of diagnosis.

Annals of Oncology, 2020

p< 0.01), n-6/n-3 (p¼0.042) as compared with locoregional CRC, was noted for patients with liver ... more p< 0.01), n-6/n-3 (p¼0.042) as compared with locoregional CRC, was noted for patients with liver metastases. ROC curve was plotted for the panel of metabolites to demonstrate the ability to predict the presence of liver metastases or locoregional CRC. The area under the ROC curve was 0.90 with a sensitivity of 0.79 and a specificity of 0.89. We found the list of metabolites capable of identifying differences between patients with liver metastases and extrahepatic metastases: serum levels of myristic acid (C14:0), linoleic acid (C18:2;n-6), phenylalanine, threonine were lower and glutamine, glucose, butanoic acid, histidine, and mannose were more abundant in extrahepatic metastases in comparison with patients with liver metastases (p< 0,01-0,05). In erythrocyte membranes the decreased content of C12:

Value in Health, 2018

recommendations were assigned to the LHUs, in the under-use areas, where there is indication but ... more recommendations were assigned to the LHUs, in the under-use areas, where there is indication but there's no prescription, and areas of over-use, where there's a prescription but there is no indication. With respect to LMWH, an indicator has been assigned that measures the percentage of patients treated with LMWH with a duration of therapy greater than the maximum duration reported in the SPC. The choice of indicators was shared with the clinicians. To LHUs has been assigned the mission of disseminating the indicators through audit initiatives with the prescribers. RESULTS: In the two-year period 2016-2017, regional expenditure by LMWH decreased by over V 4 million, compared to an almost stable trend in the years preceding the introduction of the indicators. The overall performance of the indicator improved by 2%, with peaks of over 4% in some LHUs. The LHUs that have improved the performance have reduced the cost for patient treated with LMWH. CONCLUSIONS: Through the application of appropriateness indicator, leading to an improvement in the health outcomes, a financial objective has been achieved, contributing to the sustainability of the RHS.

European Journal of Cancer, 2017

disease, significant benefit consideration and applicant categorization (Table 1). At the time of... more disease, significant benefit consideration and applicant categorization (Table 1). At the time of OD application, 41.6% of products with OD for rare neoplastic disorders was in preclinical phase, while this was 65.1% of OD for other rare indications (p < 005). Thirty percent of agents for rare neoplastic disorders reached phase 1 clinical trials, whilst this was only 19.3% of agents for other rare indications (p < 005). The same trend was observed for the stage of development at the time of the latest annual report. Conclusion: The products that have been granted OD for rare neoplastic disorders are at a later stage of development compared to OD products for other rare indications. Conflict of interest: Advisory Board: MC is a member of the Scientific Advice Working Party (SAWP) at European Medicines Agency (EMA); KL is head of Orphan Medicines at European Medicines Agency (EMA). Other Substantive Relationships: A donation from Sanofi-Genzyme to KU Leuven covered some research costs; KP is funded by Flanders Innovation & Entrepreneurship.

EC Clinical and Medical Case Reports, Apr 28, 2021

Patients suffering from chronic inflammatory rheumatism are vulnerable; they have an increased ri... more Patients suffering from chronic inflammatory rheumatism are vulnerable; they have an increased risk of bacterial and viral infections, related to the systemic and dysimmune inflammation of the chronic disease and the use of various immunosuppressive therapies. This risk explains the practice of periodic preventive vaccination adopted by all. As a result, patients with chronic inflammatory rheumatism (RIC) are more likely to contract COVID-19 and present severe forms. As with various international societies, the members of the two Algerian rheumatology societies (SAR "Algerian Society for Rheumatology" and LAAR "The Algerian League Against Rheumatism") propose these recommendations. They include general and preventive measures relating to the different situations encountered; management of patients without signs of Covid-19 (SCov-), management of suspected cases (SCov+), management of confirmed cases (SCov+) and management of newly diagnosed cases, recommendations for specific situations, those relating to pregnant women and vaccinations.

EC Clinical and Medical Case Reports, Apr 28, 2021

Journal of Clinical Oncology and Cancer Research, 2021

Journal of Clinical Oncology and Cancer Research, 2021

Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is ... more Oncology practice during COVID -19 pandemic faced many challenges one of the major challenges is adaptation of treatment protocols for achieving following objectives. Managing system capacity, Enhancement of patient’s outcomes (quality of life – economic value – clinical effectiveness). And utilizing the resources during this hard times. Previous objectives raised many questions about nature of treatment protocols should be implemented during COVID -19. Pandemic and how innovative medicines can achieve the previous objectives.

Research Journal of Oncology, 2019

Background: Head and neck cancer accounts for a range of 4-14% of all cancer cases seen. It is es... more Background: Head and neck cancer accounts for a range of 4-14% of all cancer cases seen. It is estimated to be 3700 new cases/year. Locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) accounts for 47.5-75% of all head and neck cancer. With the development of innovative and targeted therapy for treatment of some questions was raised from payer side need an answer such as: are these innovative products worthy for reimbursement? What is the impact on budget? What is the appropriate use and indication for these products to enhance outcomes and utilize resources?

EC Clinical and Medical Case Reports, Sep 30, 2021